PRTN3 and autoimmune disease: The disease-specificity of the ACPA and anti-CarP immune responses, as well as the evidence for the involvement of the corresponding protein modifications and these antibodies in pathophysiological processes, strongly suggest that modulation of citrullination and/or carbamylation might be a potential therapeutic approach to treat patients with RA and other autoimmune diseases associated with these modifications.